August 27, 2019
The Pharmaceuticals and Medical Devices Agency (PMDA) is reviewing a new risk for Amgen Astellas BioPharma’s osteoporosis drug Evenity (romosozumab) - a move that is likely to result in label changes. The drug is being reviewed for risks associated with...read more